BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 19807240)

  • 1. The role of fentanyl in cancer-related pain.
    Prommer E
    J Palliat Med; 2009 Oct; 12(10):947-54. PubMed ID: 19807240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients: an overview of its pharmacological and clinical characteristics.
    Mystakidou K; Katsouda E; Parpa E; Tsiatas ML; Vlahos L
    Am J Hosp Palliat Care; 2005; 22(3):228-32. PubMed ID: 15909786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Managing breakthrough pain: a clinical review with three case studies using oral transmucosal fentanyl citrate.
    Rhiner M; Palos G; Termini M
    Clin J Oncol Nurs; 2004 Oct; 8(5):507-12. PubMed ID: 15515284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new transmucosal fentanyl for breakthrough cancer pain.
    Rospond RM
    Cancer Pract; 1999; 7(6):317-20. PubMed ID: 10732531
    [No Abstract]   [Full Text] [Related]  

  • 5. Use of intravenous fentanyl against morphine tolerance in breakthrough cancer pain: a case series and literature review.
    Hwang IC; Bruera E; Park SM
    Am J Hosp Palliat Care; 2014 Feb; 31(1):109-11. PubMed ID: 23345613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fentanyl nasal spray (Lazanda) for pain.
    Med Lett Drugs Ther; 2011 Dec; 53(1379-1380):99-100. PubMed ID: 22173454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An economic evaluation of short-acting opioids for treatment of breakthrough pain in patients with cancer.
    Vissers DC; Lenre M; Tolley K; Jakobsson J; Sendersky V; Jansen JP
    Value Health; 2011; 14(2):274-81. PubMed ID: 21402296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer-related breakthrough pain.
    Davies AN
    Br J Hosp Med (Lond); 2006 Aug; 67(8):414-6. PubMed ID: 16918095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients: an overview of its pharmacological and clinical characteristics.
    Mystakidou K; Katsouda E; Parpa E; Tsiatas ML; Vlahos L
    J Opioid Manag; 2005; 1(1):36-40. PubMed ID: 17315410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fentanyl buccal tablet: faster rescue analgesia for breakthrough pain?
    Lecybyl R; Hanna M
    Future Oncol; 2007 Aug; 3(4):375-9. PubMed ID: 17661711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral transmucosal fentanyl citrate: overview of pharmacological and clinical characteristics.
    Mystakidou K; Katsouda E; Parpa E; Vlahos L; Tsiatas ML
    Drug Deliv; 2006; 13(4):269-76. PubMed ID: 16766468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral transmucosal fentanyl: new preparation. For breakthrough cancer pain when morphine fails.
    Prescrire Int; 2002 Aug; 11(60):106-7. PubMed ID: 12199262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fentanyl buccal tablet (Fentora) for breakthrough pain.
    Med Lett Drugs Ther; 2007 Sep; 49(1270):78-9. PubMed ID: 17878889
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy and safety of fentanyl sublingual spray for the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study.
    Rauck R; Reynolds L; Geach J; Bull J; Stearns L; Scherlis M; Parikh N; Dillaha L
    Curr Med Res Opin; 2012 May; 28(5):859-70. PubMed ID: 22480131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Use of fendivia transdermal therapeutic system in Russian patients with malignant neoplasms during palliative care: pharmacoeconomic aspects].
    Ryazhenov VV; Abuzarova GR; Gorokhova SG; Emchenko IV; Matveev NV
    Ter Arkh; 2014; 86(2):63-8. PubMed ID: 24772510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety alert for fentanyl buccal tablets.
    U.S. Food and Drug Administration
    J Pain Palliat Care Pharmacother; 2008; 22(1):47. PubMed ID: 19062355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of oral transmucosal fetanyl citrate in the management of breakthrough cancer pain.
    Rees E
    Int J Palliat Nurs; 2002 Jun; 8(6):304-8. PubMed ID: 12131825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of oral formulations of fentanyl for breakthrough cancer pain.
    Handsaker S; Dempsey L; Fabby C
    Int J Palliat Nurs; 2015 Apr; 21(4):168, 170-2. PubMed ID: 25901588
    [No Abstract]   [Full Text] [Related]  

  • 19. Fentanyl (transmucosal).
    Twycross R; Prommer EE; Mihalyo M; Wilcock A
    J Pain Symptom Manage; 2012 Jul; 44(1):131-49. PubMed ID: 22770488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opioids for management of breakthrough pain in cancer patients.
    Potter MB
    Am Fam Physician; 2006 Dec; 74(11):1855-7. PubMed ID: 17168339
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.